ATS 2024 Final Program

Click on the session title to view the speakers

145

MONDAY • MAY 20

P1448 Comparison of an Experimental Sepsis Definition Using a Cellular Host-response Test to Consensus Definitions for Risk Stratification in the ED P1449 Breath-driven Diagnostics: A Noninvasive In Vitro Assay for Lower Respiratory Tract Infections Using Multiplexed Protease Sensors in ICU Settings P1450 Neutrophils Phenotype and Function After Isolation From Very Low Volume of Blood - A Perspective in Sepsis Patients P1451 Acetate, A Gut Microbial Metabolite, Is Elevated in Experimental Sepsis and Correlates With Disease Severity P1452 Wwox: A Risk Factor for Severity and Neuroinflammation in Experimental Sepsis P1453 Transcutaneous Monitoring of CO2 for Improved Specificity for Detection of Sepsis P1454 Bronchoalveolar Lavage and Serum Citrullinated Histone H3 Concentrations Differentiate Patients With Sepsis Versus Non-sepsis-induced Acute Respiratory Distress Syndrome P1455 Identification and Analysis of Necroptosis-related Genes in Sepsis by Bioinformatics Analysis and Experimental Verification P1456 A “Net” Benefit? Measuring Citrullinated Histone H3 to Estimate Neutrophil Extracellular Trap (NET) Formation in Critically Ill Patients P1457 Novel Next-generation Non-catalytic P38alpha/MK2 Immunomodulators With Endothelial-barrier-stabilizing and Anti-inflammatory Activity P1458 Endothelial Glycocalyx-derived Dermatan Sulfate Is Associated With Sepsis Diagnosis and Microvascular Dysregulation P1459 Safety and Tolerability of Inhaled Physiological Aqueous Chlorine: Potential for Acute Respiratory Distress Syndrome P1460 Developing a Novel Oxygen Carrier for Resuscitation and Oxygen Delivery Through Targeted Mutations of Recombinant Heme Proteins P1461 Clinical Value of Exhaled Breath Condensate-GM in the Diagnosis of Invasive Pulmonary Aspergillosis

P987 The Impact of COVID-19 Co-diagnosis on Sepsis-related Hospitalization and Mortality in 2020 Using the NIS Database P988 Barotrauma in Mechanically Ventilated COVID-19 Patients With Severe ARDS P989 CANCOV- Canadian Prospective Cohort of 1-year Outcomes in Critically Ill Patients With COVID-19 and Their Family Caregivers - Preliminary Report on Causes of Death in the ICU Cohort P990 Comparison of Outcomes in COVID-19 Patients Receiving Early Versus Late Tracheotomy P991 Derivation of a Prognostic Model for Predicting the Need for Invasive Mechanical Ventilation at Hospital Admission and the Following 12 Hours in COVID-19 Patients P992 Continuous Non-invasive Inhaled Nitric Oxide Through High Flow Nasal Cannula Is Feasible and Might Mitigate the Need for Intubation in Severe COVID-19 Pneumonia: A Retrospective Study P993 Trends and Outcomes on the Impact of Diabetes Among Patients Hospitalized With COVID-19 Infection: 2020 National Inpatient Sample Analysis P994 Impact of Intubation Timing on Clinical Outcomes in Critically Ill COVID-19 Patients With Respiratory Failure P995 The Changing Demographics and Severity in Hospitalized Patients Across COVID-19 Variants: A National Cohort Study P996 How Did Respiratory Support Management and Patients’ Demographics Change in the ICU Before, During, and After the Pandemic?

BASIC • CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

B41 INNOVATION INCUBATOR: NOVEL SEPSIS MECHANISMS AND MARKERS 9:15 a.m. - 4:15 p.m. San Diego Convention Center Area L (Hall H, Ground Level) Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees

ATS 2024 Conference Program • San Diego, CA